G-Link enables targeted in vivo delivery and streamlines ex vivo workflows without lentiviral vector reengineering G-Link supports multiple delivery...
United Immunity, Co., Ltd., a biotechnology company developing its proprietary Myeloid Targeting Platform™ for therapeutic in vivo engineerin...
Myosin Therapeutics, a clinical stage biotechnology company developing innovative therapies for oncology, announced that the first patient has been dosed...
Clearance Recognises CellDx-Tissue's Dual-Analyte DNA and RNA Workflow Across 517 Cancer-Associated Genes, with ALK, RET and ROS1 Fusion Calls on RNA-Lev...
New Gibco™ CTS™ DynaXS™ Single Use Bioreactor supports flexible, cGMP-ready cell expansion from process development to clinical p...
Valerio Therapeutics (FR0010095596 – ALVIO), a biotechnology company specializing in the development of technology platforms dedicated to the targe...
Central nervous system (CNS) cancers remain among the most difficult diseases to treat in oncology, with limited therapeutic options, complex deliv...
Fluid overload remains one of the most complex and costly challenges in cardiorenal care, particularly for patients who no longer respond to conventional d...
Analytical Framework Combines AI-Powered Retinal Imaging with Proprietary Circular RNA Biomarkers to Unlock Scalable, Non-Invasive Pathway for Early-Stag...
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that it has signed a definitive agreement to sell its microbiol...
Regenerative medicine is entering a pivotal phase, shifting from long-standing scientific promise toward practical clinical application. BioRestorative The...
PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, and Covaris, a PerkinElmer company and leader in sample...
- Myriad Genetics Inc., a leader in molecular diagnostic testing and precision medicine,announced that Japan’s Ministry of Health, Labour and...
Dataset will drive crucial insights to accelerate scientific discovery and ultimately improve pediatric patient care. Illumina (NASDAQ: ILMN) and...
© 2026 Biopharma Boardroom. All Rights Reserved.
